In colorectal cancer, miR-497 targets VEGF-A, leading to blockade of the VEGF-A/ERK/MMP-9 signaling pathway and the attenuation of tumor angiogenesis, invasion, and metastasis [105]. Here, MMP9 is linked to neoplasm.